Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 10 of 11
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Changes in mental health following COVID-19 infection: Results of a prospective cohort study in Mongolia
    (Mongolian National University of Medical Sciences, 2026-03-30)
    aa Enkhtuvshin Regzed
    ;
    Mongoljin Altankhuyag
    ;
    ; ;
    Yelik Madi
    Objective: COVID-19 has been associated with persistent neuropsychiatric complications, yet prospective evidence from low- and middle-income countries remains limited. This study evaluated 12-month longitudinal changes in depression, anxiety, insomnia, and post-traumatic stress disorder (PTSD) among hospitalized patients with COVID-19 compared with non-COVID-19 controls in Mongolia. Methods: This prospective cohort study included 459 adults (326 COVID-19 cases and 133 controls) recruited from hospitals affiliated with the Mongolian National University of Medical Sciences between 2021 and 2023. Participants without baseline mental disorders were assessed at 7–14 days, 3 months, and 12 months using the PHQ-9, GAD-7, ISI, and PCL-5. Data were analyzed using X² tests, independent t-tests, and relative risk (RR) estimates, with statistical significance defined as p < 0.05. Results: The mean age of participants was 46.3 ± 13.8 years, and 58.4% were female. At 12 months, depression (37.3% vs. 16.9%; RR = 2.22, 95% CI: 1.28–3.83; p = 0.003) and anxiety (28.0% vs. 11.2%; RR = 2.49, 95% CI: 1.25–4.96; p = 0.006) remained significantly more common in the COVID-19 group than in controls. Insomnia decreased over time (33.3% vs. 49.4%; RR = 0.67; p = 0.037), whereas PTSD prevalence remained low in both groups (<3%, p > 0.05). Female participants and those aged 40–59 years showed a higher risk of adverse mental health outcomes. Conclusions: COVID-19 infection was associated with a significantly increased long-term risk of depression and anxiety up to 12 months after infection. These findings support routine mental health screening and sustained psychological follow-up as part of post-COVID care and provide evidence to inform long-term mental health policy in Mongolia.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Correlation Between Maternal-Neonatal Vitamin D Status and it’s Related to Supplementation in Mongolian Pregnant Women
    Background: Vitamin D deficiency and insufficient in pregnancy can lead to fetal deficiency that may affect chronic disease susceptibility childhood and adulthood. The aim of this study is to investigate the correlation between maternal and neonatal Vitamin D levels at birth and to identify other risk factors among pregnant women in Mongolia. Methods: Hospital-based study was conducted on 528 participants which included 264 mothers and 264 neonates. Pre-delivery maternal blood and neonatal cord blood samples were collected after birth. 25(ОН)D concentration was analyzed in relation to neonatal Vitamin D status, maternal and neonatal characteristics, and maternal Vitamin D intake. Results: The majority of Vitamin D levels in both maternal (76.5%) and neonatal cord (90.5%) blood were in the deficiency range. Only 3.8% of mothers and 1.5% of neonates had levels in the sufficient range at the time of delivery. For maternal demographic factors, total income was significantly different between the groups (P=0.000). The maternal outcomes were no significant associations were found between groups, but neonatal outcomes were associated with maternal Vitamin D status. In terms of Vitamin D supplementation, 27% of women were taken during pregnancy. Of the not supplemented women, 80% were Vitamin D deficient. Conclusions: A high proportion of Vitamin D deficiency was found in both mothers and newborns in our study. There is a strong correlation between the amount of Vitamin D in the mother and in the newborn. A mother’s Vitamin D intake is related to Vitamin D levels in the mother’s blood.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Vitamin D Status in Mongolian Pregnant Women and Birth Outcomes
    (Mongolian National University of Medical Sciences, 2021-12-31) ;
    Gerelmaa Zagd
    ;
    ; ;
    Objectives:Vitamin D deficiency and insufficiency in pregnancy can lead to gestational diabetes, preeclampsia, and eclampsia, as well as newborns having Vitamin D deficiency. This study was performed to determine the amount of maternal, neonatal Vitamin D, and consequences of Vitamin D deficiency on birth outcomes. Methods: Hospital-based prospective research was conducted on 528 participants which included 264 mothers and 264 neonates. Pre-delivery maternal venous blood and neonatal cord blood samples were collected and total 25(OH)D concentration was measured. After checking the normality of data distribution, methods of result presentation and statistical analyses were applied. Results: The average level of 25(OH) D in the mother’s blood was 16.53 ± 6.5 ng/ml. The total Vitamin D deficiency in mothers was 191 (72.3%), insufficiency was 63 (23.9%), and 10 (3.8%) registered levels of sufficiency. Maternal serum 25(OH)D was significantly correlated with cord blood 25(OH)D (r = 0.87, p < 0.01). Conclusion: A high proportion of Vitamin D deficiency was found in both mothers and newborns in our study. There is a strong correlation between the amount of Vitamin D in the mother’s blood and in the umbilical cord blood of the newborn. Complications of pregnancy are not associated with Vitamin D status in mother’s blood.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Functional Abnormalities of the Liver in Diabetic Patients with and without Hepatitis C
    (Mongolian National University of Medical Sciences, 2019-03-31) ; ; ; ;
    Objective: We aimed to compare liver function of diabetes mellitus patients with and without viral hepatitis C using the non-alcoholic fatty liver disease fibrosis score, aspartate transaminase to platelet ratio index, Fibrosis-4 Index, Mac-2-binding protein biomarker and ultrasonic liver stiffness measurements. Methods: The study was conducted based on convenience sampling of 123 patients. Slightly more than half of the study participants were male (53%, n=64). Thirty-three of the diabetics with hepatitis (mean age 52.31±9.8 years) and 90 diabetics without hepatitis (mean age 53.26±8.58) agreed to participate. Anthropometric measurements, non-alcoholic fatty liver disease fibrosis score, aspartate transaminase to platelet ratio index, Fibrosis-4 Index, Mac-2-binding protein biomarker, and ultrasonic transient elastography measurements were compared using independent t-tests for continuous variables and Wilcoxon rank sum tests for ordinal variables. Results: The median values of the Fibrosis-4 Index for those with and without hepatitis C were 1.3 vs. 0.9 (p<.05), Mac-2-binding protein biomarker 2.0 vs. 1.3 (p<.0001), ultrasonic liver stiffness measurements 10.3 vs. 6.9 (p<.0001), aspartate transaminase to platelet ratio 0.6 vs. 0.3 (p<.001), and Non-alcoholic fatty liver disease fibrosis scores were -0.2 vs. -0.9 ( p<.004), respectively Conclusions: Diabetic patients with hepatitis had statistically significantly higher Mac-2-binding protein biomarker, NAFLD Fibrosis Scores than patients without hepatitis. However, other fibrosis test results were similar in diabetic patients with hepatitis and without hepatitis C.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Establishment of Reference Interval for M2BPGI Glyco-Biomarker in the Serum of Mongolian People
    (Mongolian National University of Medical Sciences, 2020-12-29) ; ; ; ;
    Objectives: Establishment of reference interval for M2BPGI glyco-biomarker in the serum of relatively healthy Mongolian people. Methods: Serum analysis for M2BPGI glyco-biomarker, hepatitis virus markers, and AFP analysis were performed using a fully automated chemiluminescence immunoassay analyzer. Non-parametric methods were used for establishment of reference interval according to the guideline of the Clinical Laboratory Standards Institute. Statistical analysis was done by using SPSS ver. 20.0; SPSS Inc., Chicago, IL software. Results: Total of 3384 people were involved in this study. Of the total participants, 40% were overweight and 31.3% were obese. Also, of the population 10.1 percent were positive for HBsAg, 17 percent were positive for Anti-HCV, and 1.1 percent had co infection of both HBV and HCV. A total of the 316 individuals met the inclusion criteria for reference interval establishment and 77 (24.4%) of them were men and 239 (75.6%) were women. The reference interval of M2BPGI glyco-biomarker for men was 0.883 ± 0.311C.O.I and for women was 0.951 ± 0.411C.O.I. Conclusion: It is determined that the reference interval for M2BPGI glyco-biomarker in the serum of relatively healthy Mongolian people was 0.936 ± 0.391C.O.I.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Risk Factors for Hepatitis B and C Infection in 10 to 40 Year Olds in Mongolia
    (Mongolian National University of Medical Sciences, 2019-12-29) ; ; ; ;
    Objective: To determine the prevalence of hepatitis B and C infection and its risk factors in Mongolians from 10 to 40 years of age. Method: Randomly selected Mongolians underwent phlebotomy and completed a questionnaire about their medical and family history and risk factors. Participants were screened for qHBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc markers, and Anti-HCV. Results: 6811 people, 2900 (42.7%) males, and 3911 (57.3%) females participated. Most were from Ulaanbaatar (4685, 69%), with the remaining 2126 (31%) from rural areas. Seven percent were HbsAg positive, 4.2% were HCV positive. Of those10-20 years of age, 5.8% (29) had hepatitis B, 6% (17) had hepatitis C. Of those 21 to 40 years of age, 94.2% (469) had hepatitis B, and 94%(268) had hepatitis C. Children whose mother was HBsAg positive were at higher risk of HBsAg positivity (OR 2.152; 95% CI 1.4; 3.2, p < .0001) as well as those with male gender (OR 1.703; 95% CI 1.17;2.46, p < .005), those phlebotomized for lab tests (OR 1.768; 95% CI 1.14; 2.74, p = .011) ,and those immunized against hepatitis B (OR 0.508; 95% CI 0.35; 0.74, p < .0001). HCV infection was associated with history of dental procedures (OR 1.681; 95% CI 1.01; 2.79, p = .045), using glass syringes (OR 2.131; 95% CI 1.54; 2.95, p < .0001), and previously used needles (OR 2.411; 95% CI 1.09;5.29, p = .028). Conclusions: Among the Mongolian population between 10 and 40 years of age, 7.3% were HbsAg positive, 4.2% were Anti-HCV positive. The risk factors were maternal HbsAg positivity, utilization of glass syringes, reusing needles, phlebotomy for laboratory tests, receiving dental treatment, and the absence of hepatitis B immunization.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Results of the National Study of CLEIA Method for the Prevalence of HBV and HCV in the 40-64 Age Population of Mongolia
    (Mongolian National University of Medical Sciences, 2019-09-25) ; ; ; ;
    Objective: Using high-sensitivity test results of CLEIA we aimed to investigate the prevalence of hepatitis B and C virus, and compare levels of AST, ALT, M2BPGI in the Mongolian population in the age between 40-64. Methods: In order to reflect the administrative and geographical features of Mongolia, the sampling was done at three levels: urban, province center, and rural. Immunological test was measured by chemiluminescence enzyme immunoassay (CLEIA). The statistical package for the social sciences (SPSS) version 25 was used for the statistical analyses. Results: The survey covered 3196 people. 71.8 percent of the patients surveyed had a negative in hepatitis test. 10.1 percent had a positive HBsAg test. 17 percent had a positive anti-HCV test. 1.1 percent had both a positive both HBsAg and anti-HCV (<.0001). AST and ALT increased more frequently during co-infection. M2BPGI protein average level in the non-infected group was 1.00 C.O.I, in the HBsAg positive group 1.65 C.O.I, in the anti-HCV positive group 1.83 C.O.I, and in the co-infection group 1.87 C.O.I (<.0001). Conclusion:10.1 percent of 40-64year-olds in Mongolia were infected with hepatitis B virus, and 17 percent had Hepatitis C virus and 1.1 percent had hepatitis B and C virus co-infections. Serum M2BPGi is increasing in hepatitis C virus infection and in co-infection.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study
    (The Korean Association for the Study of the Liver, 2021-01) ;
    Lee, Jae Seung
    ;
    Amarsanaa, Jazag
    ;
    ;
    Ahn, Sang Hoon
    BACKGROUND/AIMS: Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients. METHODS: Between 2015 to 2019, 23 (0.5%) and 5,005 patients (99.5%) with genotype 1a and 1b HCV, respectively, were treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 12 weeks, and 81 patients (1.6%) with previous experience of interferon (IFN)-based treatment received additional 1,000 mg ribavirin. HCV RNA was measured at 4, 12, and 24 weeks after the first dose to determine rapid virologic response, end of treatment response (ETR), and sustained virologic response at 12 weeks after end of treatment (SVR12). RESULTS: Most patients (n=5,008; 99.6%) achieved ETR and SVR12 without virologic relapse. Patients with genotype 1a showed low rates of ETR and SVR12 in only 16 patients (69.6%). There was no significant difference in SVR12 rate between patients regardless of IFN experience (n=81; 1.6%), cirrhosis (n=1,151; 22.9%), HCV RNA >6×106 IU/mL (n=866; 17.2%), or liver stiffness >9.6 kPa (n=1,721; 34.2%) (100.0%, 99.3%, 99.4%, and 99.4%, respectively). No severe adverse events (AEs) were reported, and there was no dose reduction or interruption due to AE. The most common AEs were headache (n=472; 9.4%), fatigue (n=306; 6.2%), abdominal discomfort (n=295; 5.9%), and skin rash (n=141; 2.8%). CONCLUSION: LDV/SOF showed high efficacy and safety for patients with genotype 1, especially 1b HCV, in Mongolia. The real-world data might be applicable to patients in other Asian-Pacific countries.
    Scopus© Citations 5
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Scopus© Citations 4